Raymond James Financial Inc. Acquires Shares of 139,591 Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Raymond James Financial Inc. bought a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 139,591 shares of the company's stock, valued at approximately $498,000. Raymond James Financial Inc. owned about 0.15% of Aquestive Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Harvey Capital Management Inc. lifted its stake in Aquestive Therapeutics by 1,419.3% during the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company's stock valued at $952,000 after purchasing an additional 249,790 shares during the last quarter. Vanguard Group Inc. lifted its stake in Aquestive Therapeutics by 1.9% during the fourth quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company's stock valued at $15,474,000 after purchasing an additional 82,958 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Aquestive Therapeutics by 233.6% during the fourth quarter. Renaissance Technologies LLC now owns 95,400 shares of the company's stock valued at $340,000 after purchasing an additional 66,800 shares during the last quarter. SG Americas Securities LLC lifted its stake in Aquestive Therapeutics by 28.7% during the fourth quarter. SG Americas Securities LLC now owns 32,966 shares of the company's stock valued at $117,000 after purchasing an additional 7,347 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its stake in Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock valued at $43,000 after purchasing an additional 10,700 shares during the last quarter. 32.45% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AQST. Alliance Global Partners reissued a "buy" rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Lake Street Capital reduced their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Friday, March 7th. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday, April 2nd. Finally, Raymond James set a $7.00 price target on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Aquestive Therapeutics presently has an average rating of "Buy" and an average target price of $10.67.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ:AQST traded up $0.06 during mid-day trading on Monday, hitting $2.85. The stock had a trading volume of 1,315,565 shares, compared to its average volume of 1,452,269. The company has a market cap of $283.06 million, a PE ratio of -6.33 and a beta of 2.02. Aquestive Therapeutics, Inc. has a 12-month low of $2.20 and a 12-month high of $5.80. The company's 50 day moving average is $2.78 and its 200-day moving average is $3.45.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.07). On average, equities research analysts predict that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.